Angehrn P, Hohl P, Hubschwerlen C, Page M, Then R
Preclinical Research, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Antimicrob Agents Chemother. 1992 Dec;36(12):2825-34. doi: 10.1128/AAC.36.12.2825.
Ro 41-3399 is a novel orally active ester of Ro 40-6890, an aminothiazolyl cephalosporin with potent in vitro activities against commonly encountered aerobic gram-positive bacteria (streptococci and methicillin-susceptible staphylococci) and gram-negative bacteria (members of the family Enterobacteriaceae, haemophili, meningococci, and gonococci). In terms of the MICs determined by the methods recommended by the National Committee for Clinical Laboratory Standards, for 50 and 90% of gram-positive organisms, the water-soluble free carboxylic acid Ro 40-6890 proved to be at least as active as or two- to fourfold more active than cefpodoxime, cefuroxime, cefaclor, amoxicillin, amoxicillin-clavulanic acid, and ceftriaxone; against aerobic gram-negative organisms, Ro 40-6890 was usually two- to fourfold more active than cefpodoxime, the next most potent of the oral drugs under comparison, but remained usually two- to fourfold weaker than ceftriaxone. Ro 40-6890 showed a high affinity for the essential penicillin-binding proteins of susceptible bacteria and was resistant to hydrolysis by a broad array of beta-lactamases. Ro 41-3399 bopentil was well absorbed in mice when administered by oral gavage and proved effective in several experimental bacterial infections. Further studies with Ro 41-3399 and Ro 40-6890 are in progress.
Ro 41-3399是Ro 40-6890的一种新型口服活性酯,Ro 40-6890是一种氨基噻唑基头孢菌素,对常见的需氧革兰氏阳性菌(链球菌和甲氧西林敏感葡萄球菌)和革兰氏阴性菌(肠杆菌科成员、嗜血杆菌、脑膜炎球菌和淋球菌)具有强大的体外活性。根据美国国家临床实验室标准委员会推荐的方法测定的最低抑菌浓度(MIC),对于50%和90%的革兰氏阳性菌,水溶性游离羧酸Ro 40-6890的活性至少与头孢泊肟、头孢呋辛、头孢克洛、阿莫西林、阿莫西林-克拉维酸和头孢曲松相当,或比它们高两到四倍;对于需氧革兰氏阴性菌,Ro 40-6890的活性通常比头孢泊肟高两到四倍,头孢泊肟是所比较的口服药物中活性次之的,但通常仍比头孢曲松弱两到四倍。Ro 40-6890对敏感细菌的必需青霉素结合蛋白具有高亲和力,并且对多种β-内酰胺酶具有抗性。Ro 41-3399波喷替通过口服灌胃给药时在小鼠体内吸收良好,并在几种实验性细菌感染中证明有效。对Ro 41-3399和Ro 40-6890的进一步研究正在进行中。